Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Janssen Biotech submits NDA to FDA for apalutamide to treat non-metastatic CRPC

pharmaceufical-technologyOctober 13, 2017

Tag: Janssen Biotech , FDA , CRPC

PharmaSources Customer Service